Chiasma Reports Results of Mycapssa (octreotide) in P-III CHIASMA OPTIMAL Study as a Maintenance Therapy for Acromegaly

 Chiasma Reports Results of Mycapssa (octreotide) in P-III CHIASMA OPTIMAL Study as a Maintenance Therapy for Acromegaly

Chiasma Reports Results of Mycapssa (octreotide) in P-III CHIASMA OPTIMAL Study as a Maintenance Therapy for Acromegaly

Shots:

  • The P-III CHIASMA OPTIMAL study involves assessing of Mycapssa formulated as capsules vs PBO in 56 patients in a ratio (1:1) with acromegaly prior treated with somatostatin analogs for 9mos., conducted under a SPA agreement with FDA
  • The P-III CHIASMA OPTIMAL study results: met its 1EPs & 2EPs; maintained IGF-1 response (58% vs 19%); maintained GH level below 2.5 ng/mL (78% vs 30%); requirement of rescue medication (25% vs 68%); safe & well tolerated
  •  Mycapssa is an oral formulation of the somatostatin analog octreotide, currently in development for the treatment of acromegaly with its expected NDA submission for octreotide capsules in H2’19

Click here to read full press release/ article | Ref: Chiasma | Image: Chiasma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post